

Pfizer Ltd

Ramsgate Road

Revision date: 22-Jul-2009 Version: 2.0 Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Dalteparin Sodium Injection

Trade Name: Fragmin Injection

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as anticoagulant agent

2. HAZARDS IDENTIFICATION

Appearance: Clear, colorless to light yellow solution

Signal Word: WARNING

Statement of Hazard: May cause allergic skin reaction.

Additional Hazard Information:

Short Term: Mild eye irritant in experimental animals

Known Clinical Effects: Clinical use of this drug has caused hemorrhage, gastrointestinal bleeding, increased bleeding

time. Individuals sensitive to this material or other materials in its chemical class may develop

allergic reactions.

EU Indication of danger: Irritant

EU Hazard Symbols:



EU Risk Phrases:

R43 - May cause sensitization by skin contact.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

Material Name: Dalteparin Sodium Injection Page 2 of 6

Revision date: 22-Jul-2009 Version: 2.0

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Dalteparin Sodium (Heparin Sodium)	9041-08-1	Not listed	Xi;R43	5-12

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Sodium chloride	7647-14-5	231-598-3	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fine / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Material Name: Dalteparin Sodium Injection Page 3 of 6 Revision date: 22-Jul-2009 Version: 2.0

Additional Consideration for Large

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use

> appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled

with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium chloride

Latvia OEL - TWA Listed Lithuania OEL - TWA Listed

Dalteparin Sodium (Heparin Sodium)

Pfizer OEL TWA-8 Hr: 200µg/m³

Analytical Method: Analytical method available for Dalteparin Sodium. Contact Pfizer Inc for further information. **Engineering Controls:**

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eves: Wear safety glasses or goggles if eye contact is possible. Wear protective clothing when working with large quantities. Skin:

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL **PROPERTIES**

Physical State: Solution Color: Colorless to pale straw-

color

Molecular Formula: Mixture **Molecular Weight:** Mixture

Soluble: Water Solubility:

pH: 5.0-7.5 Specific Gravity: 1.04

Material Name: Dalteparin Sodium Injection Page 4 of 6
Revision date: 22-Jul-2009 Version: 2.0

Vol. 51.51.51.

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Dalteparin Sodium (Heparin Sodium)

Rat Oral LD 50 > 5000 mg/kg Mouse Oral LD 50 > 5000 mg/kg

Mouse Intraperitoneal LD 50 > 2500 mg/kg Rat Intraperitoneal LD 50 2500 mg/kg Mouse Intravenous LD 50 2800 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Dalteparin Sodium (Heparin Sodium)

Eye Irritation Rabbit Mild

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Dalteparin Sodium (Heparin Sodium)

Fertility and Embryonic Development Rat Subcutaneous 10 mg/kg/day NOAEL Fertility, Fetotoxicity

Embryo / Fetal Development Rat Intravenous 10,000 mg/kg/day LOAEL Fetotoxicity Embryo / Fetal Development Rabbit Intravenous 2,500 mg/kg/day LOAEL Fetotoxicity

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Material Name: Dalteparin Sodium Injection Page 5 of 6
Revision date: 22-Jul-2009 Version: 2.0

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xi EU Indication of danger: Irritant

EU Risk Phrases:

R43 - May cause sensitization by skin contact.

EU Safety Phrases:

S24 - Avoid contact with skin.

S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:

WARNING

May cause allergic skin reaction.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B



Sodium chloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

231-598-3

Water

Inventory - United States TSCA - Sect. 8(b)

Listed

Material Name: Dalteparin Sodium Injection Page 6 of 6
Revision date: 22-Jul-2009 Version: 2.0

15. REGULATORY INFORMATION

Australia (AICS): Listed
REACH - Annex IV - Exemptions from the Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Dalteparin Sodium (Heparin Sodium)

Inventory - United States TSCA - Sect. 8(b)ListedAustralia (AICS):ListedStandard for the Uniform SchedulingSchedule 4

for Drugs and Poisons:

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R43 - May cause sensitization by skin contact.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 -

Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet